Order results by:
| Issue | Title | |
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..." | ||
| Vol 10, No 4 (2017) | INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW | Abstract similar documents |
| D. G. Tolkacheva, A. V. Torgov, A. S. Margazova | ||
| "... Objective. In this review, we analyzed the policies for price controls on generics and biosimilars ..." | ||
| Vol 12, No 2 (2019) | Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available | Abstract similar documents |
| F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev | ||
| "... in the prices of the reference drugs that circulate together with generics/biosimilars for at least 4 years ..." | ||
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... patent protection by generics or biosimilars over 5 years was simulated. Two replacement scenarios were ..." | ||
| Vol 11, No 1 (2018) | Options to optimize the access to biosimilars: analysis and solutions | Abstract similar documents |
| O. V. Kirsanova, V. V. Omelyanovsky | ||
| "... products – biosimilars – in the Russian Federation and elsewhere (USA, EU) are addressed. We propose ..." | ||
| Vol 13, No 2 (2020) | Review of calculation methods, procedures for registration and re-registration of producer prices of medicines in the countries of the Eurasian Economic Union | Abstract similar documents |
| A. A. Leshkevich, D. S. Yurochkin, Z. M. Golant, I. A. Narkevich | ||
| "... for the generics. The authors highlighted the drawbacks of the existing procedure of the registration of prices ..." | ||
| Vol 10, No 4 (2017) | IMPROVEMENT OF PRICE REGULATION FOR INNOVATIVE MEDICINES COVERED BY THE NATIONAL BUDGET | Abstract similar documents |
| V. A. Lemeshko, N. Z. Musina, V. K. Fedyaeva | ||
| "... the therapeutic value of the drug into its consumer price. The drug pricing system existing in the Russian ..." | ||
| Vol 7, No 4 (2014) | ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva | ||
| "... study goal is to prepare a road map for development of price regulation system and system of drug ..." | ||
| Vol 5, No 1 (2012) | UN MILLENNIUM DEVELOPMENT GOALS INDICATORS ON PROBLEMS OF ACCESS TO ESSENTIAL MEDICINES AND ENHANCEMENT OF LOCAL PHARMACEUTICAL PRODUCER IN DEVELOPING COUNTRIES | Abstract similar documents |
| A. Y. Kulikov, A. G. Voskanyan | ||
| Vol 12, No 2 (2019) | Recent changes in the pharmacovigilance system in the Russian Federation and the EAEU | Abstract similar documents |
| G. N. Gildeeva, A. V. Belostotsky | ||
| "... documents on the inspection of production lines, the assessment of generic equivalence, the development ..." | ||
| Vol 8, No 3 (2015) | COMPARATIVE PHARMACOECONOMIC STUDY OF VITAMIN-MINERAL COMPLEXES FOR REHABILITATION DURING THE PERIOD OF INCREASED NEEDS FOR MICRONUTRIENTS | Abstract similar documents |
| A. Yu. Belinskaya, I. Yu. Torshin, T. R. Grishina, O. A. Gromova | ||
| "... CMC both in quality and price. Results: Based on the assessment of pharmacological quality and price ..." | ||
| Vol 7, No 4 (2014) | ANALYSIS OF GOVERNMENT PROCUREMENTS OF MEDICINES APPLIED IN RARE DISEASES THERAPY | Abstract similar documents |
| D. V. Fedyaev, V. K. Fedyaeva, V. V. Omelyanovsky | ||
| "... drugs, the level of price reduction as a result of trading, the amount and volume of purchases ..." | ||
| Vol 9, No 3 (2016) | METHOD «COST-EFFECTIVENESS» IN EVALUETION OF ATIBIOTIC TREATMENT OF ACYTR OBSTRUCTIVE BRONCHITIS IN CHILDREN IN HOSPITAL | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... ) and generic Amoxiclav (Lek d.d) were used from the group of protected penicillins (combination amoxicillin ..." | ||
| Vol 5, No 1 (2012) | MODERNIZATION OF THE MEDICAL SERVICES MARKET | Abstract similar documents |
| A. U. Kulikov | ||
| "... market. Identified non–price factors that affect consumer demand for medical services. Identified ..." | ||
| Vol 8, No 2 (2015) | CLINICAL AND ECONOMIC ANALYSIS OF THE USE OF DIFFERENT TYPES OF SYSTEMS OF VENOUS ACCESS IN THE TREATMENT OF CHILDREN WITH CANCER | Abstract similar documents |
| Maksim Yur'evich Rykov, Vladimir Georgievich Polyakov | ||
| "... . To calculate the cost price were taken «Price list of paid medical services» and Rates of the compulsory health ..." | ||
| Vol 11, No 1 (2018) | Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... здравоохранения. Внедрение в клиническую практику воспроизведенных АА даже при условиях 100% замены ими ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia | Abstract similar documents |
| I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina | ||
| "... здравоохранения. Внедрение в клиническую практику воспроизведенных АА даже при условиях 100% замены ими ..." | ||
| Vol 10, No 2 (2017) | COSTS OF ANTIRETROVIRAL DRUGS USED IN THE THERAPY OF HIV-INFECTED PATIENTS: A PHARMACOECONOMIC ANALYSIS | Abstract similar documents |
| M. B. Kubaeva, Y. Sh. Guchshina | ||
| "... -sponsored prices and the retail prices of these medications has an impact on the costs of ant-HIV therapy. ..." | ||
| Vol 9, No 3 (2016) | EARLY HEALTH TECHNOLOGIES ASSESSMENT — NEW APPROACH TO IMPROVING THE EFFICIENCY OF THE MEDICAL TECHNOLOGY DEVELOPMENT PROCESS | Abstract similar documents |
| N. Z. Musina, V. V. Omelyanovskiy, A. V. Krasheninnikova | ||
| "... trials, to predict the probability of formulary inclusion, and to define socially acceptable price. ..." | ||
| Vol 10, No 2 (2017) | THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS | Abstract similar documents |
| V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko | ||
| "... as a major criterion in negotiations on medicine prices. The existing tools for assessing the therapeutic ..." | ||
| Vol 11, No 4 (2018) | Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer | Abstract similar documents |
| N. A. Avxentyev, A. S. Makarov, M. Yu. Frolov | ||
| "... direct medical costs (price of the drugs) of using enzalutamide or abiraterone for treatment ..." | ||
| Vol 5, No 2 (2012) | WORKING OUT OF STRATEGY OF STOREKEEPING OF PHARMACEUTICAL FIRM | Abstract similar documents |
| A. I. Borodin | ||
| "... . Instability of economy during the periods of crisis, instability of prices on pharmaceutical production ..." | ||
| Vol 10, No 1 (2017) | BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS | Abstract similar documents |
| E. A. Pyadushkina | ||
| "... analysis, published reports on inflammatory bowel disease (IBD) treatment, the highest quoted prices ..." | ||
| Vol 10, No 2 (2017) | COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov | ||
| "... regimens were calculated from the registered data on the maximum selling prices of VED drugs or from ..." | ||
| Vol 7, No 3 (2014) | PHARMACOECONOMIC ANALYSIS OF THE USE OF OXALIPLATIN CHEMOTHERAPY FOR COLORECTAL CANCER.REAL (ACTUAL) CLINICAL PRACTICE DATA | Abstract similar documents |
| A. V. Pavlysh, A. S. Kolbin, A. R. Kasimova | ||
| "... .2%. Middle cover price of case report was 252,294 rubles. In average oxaliplatin therapy was effective in 83 ..." | ||
| Vol 7, No 4 (2014) | IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? | Abstract similar documents |
| V. V. Omelyanovskiy | ||
| "... , internal and external price regulation can be distinguished. External referencing system has been used ..." | ||
| Vol 8, No 1 (2015) | SOCIAL AND ECONOMIC BURDEN OF FIVE NATURAL FOCAL INFECTIONS IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. E. Platonov, N. A. Avksentyev, M. V. Avksentyeva, E. V. Derkach, O. V. Platonova, A. V. Titkov, N. M. Kolyasnikova | ||
| "... with vector-borne infectious diseases comprised 909 million rubles in prices of 2011; most of the value ..." | ||
| Vol 10, No 2 (2017) | CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES | Abstract similar documents |
| O. V. Zhukova, S. V. Kononova | ||
| "... between the original and generic drugs, and to evaluate the treatment of acute diseases. With respect ..." | ||
| Vol 8, No 4 (2015) | CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov, M. V. Avksentyeva | ||
| "... to December 2015. The data of state statistical supervision, registered limit transfer drug prices from ..." | ||
| Vol 10, No 2 (2017) | COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD | Abstract similar documents |
| E. G. Kosolapov, F. S. Kochenkov, N. L. Pogudina, D. V. Blinov, N. L. Bondarenko, A. V. Karaulov | ||
| "... , and instructions for medical use to conduct a cost analysis that was based on the prices for these medications ..." | ||
| Vol 10, No 2 (2017) | PHARMACOECONOMIC ASPECTS OF NON-SMALL CELL LUNG CANCER IMMUNOTHERAPY | Abstract similar documents |
| A. V. Rudakova, S. A. Protsenko, I. A. Koroleva | ||
| "... of treatment (in the basic version) is 5.7% lower than that for nivolumab. When prices vary within reasonable ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| "... was calculated based on the shadow budget price (i. e. determining the WTPT by the suppling party). This method ..." | ||
| Vol 11, No 3 (2018) | Pharmacoeconomic analysis of using belimumab for the treatment of systemic lupus erythematosus | Abstract similar documents |
| A. G. Tolkushin, N. L. Pogudina | ||
| "... from analysis of published clinical and observational studies. The prices of the relevant drugs were ..." | ||
| Vol 9, No 4 (2016) | FACTORS AND EFFECTS OF PRIVATE HEALTH SPENDING | Abstract similar documents |
| O. A. Zarubina, N. N. Sisigina | ||
| "... insurance) and non-discretionary factors (relative health services price, income and its distribution, age ..." | ||
| Vol 11, No 3 (2018) | Economic barriers restraining the production of therapeutic recombinant human trypsin. Use of innovative technologies to overcome them | Abstract similar documents |
| S. V. Ponomarenko | ||
| "... the medical use of recombinant trypsin is slowed by its very high price and insufficient production ..." | ||
| Vol 12, No 1 (2019) | Individual cost accounting in the management of medical organizations | Abstract similar documents |
| I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali | ||
| "... of funds for medical care provision; increase the efficiency of management decisions; justify the prices ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... of orphan drugs and to carry out state regulation of prices, to ensure increase of regional funding ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... . The costs in model are calculated on the basis of registered prices on drugs from the List of vital ..." | ||
| Vol 8, No 4 (2015) | THE COST OF NUTRITION ALTERNATIVES FOR PREMATURE INFANTS IN RUSSIA | Abstract similar documents |
| K. V. Gerasimova, M. V. Avxentyeva, I. A. Belyaeva | ||
| "... that BM became more cost-effective when the price of powdered AF was over 937 rubles per package ..." | ||
| Vol 10, No 3 (2017) | Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis | Abstract similar documents |
| E. V. Biryukova, V. I. Ignat’eva | ||
| "... ) or the ready-made mixtures (biphasic 25 or 50 lispro). The weighted average price of 1 IU insulin (according ..." | ||
| Vol 11, No 2 (2018) | Economic evaluation of postoperative hypofractionated radiation therapy in patients with breast cancer | Abstract similar documents |
| G. V. Afonin, Yu. A. Ragulin, M. V. Avxentyeva, I. A. Gulidov, S. A. Ivanov, A. D. Kaprin | ||
| "... treatment, age and molecular type of tumor. The cost of treatment was calculated from the price list ..." | ||
| Vol 12, No 4 (2019) | Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation | Abstract similar documents |
| S. K. Zyryanov, I. N. Diyakov, S. N. Avdeev | ||
| "... % fluctuations in prices for the compared products. According to the budget impact analysis, by introducing ..." | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract similar documents |
| V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
| "... of antimicrobial treatment calculated with a reference to the price and the percentage of total AMDs administered ..." | ||
| Vol 9, No 4 (2016) | THE COSTS OF REGIONAL ANESTHESIA WITH THE USE OF LEVOBUPIVACAINE, RACEMIC BUPIVACAINE AND ROPIVACAINE | Abstract similar documents |
| G. E. Ulrikh, A. V. Rudakova | ||
| "... out for medicines containing 10 ml of solution per ampoule on the basis of registered prices ..." | ||
| Vol 13, No 4 (2020) | The social-economic burden of spinal muscular atrophy in Russia | Abstract similar documents |
| A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina | ||
| "... data included governmental healthcare and insurance companies’ tariffs, price lists of commercial ..." | ||
| Vol 12, No 3 (2019) | Pharmacoepidemiological analysis of antimicrobial therapy for burn injury in the hospital settings | Abstract similar documents |
| O. V. Zhukova, E. S. Nekaeva, E. S. Khoroshavina, E. A. Kozlova, Yu. A. Dudukina, I. Yu. Arefyev | ||
| "... than other drugs because of its high efficacy in the hospital settings and its low price. We found ..." | ||
| 1 - 46 of 46 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
